Skip to content

Our Science
Medical Professionals
- Overview
- HCP Resources
Investors & Media
Patients & Advocacy
Who We Are
Contact

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (ENGOT-ov60/GOG-3052/RAMP 201): Dose Intensity and Subgroup Analysis

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (ENGOT-ov60/GOG-3052/RAMP 201): Dose Intensity and Subgroup Analysis

Terms of Use
Copyright Statement
Privacy Policy
Contact
Sitemap

Twitter
Linkedin

© 2025 Verastem, Inc. All Rights Reserved.